Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...
Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...
Stocktwits on MSN20h
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last WeekThese five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits ...
SAN JOSE, Calif. - Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $48.3 million, today announced promising results from a ...
Rani Therapeutics Holdings, Inc. (RANI) stock price is 1.43 and Rani Therapeutics Holdings, Inc. (RANI) 10-day simple moving average is 1.36. Rani Therapeutics Holdings, Inc. (RANI) stock price is ...
SAN JOSE, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...
- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting transenteric ...
Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback